anti-DPP3 + anti-bio-ADM

The therapeutic combination of **anti-DPP3** and **anti-bio-ADM** antibodies is being evaluated as part of the ShockCO-OP research program at Saint-Louis Hospital, Paris, to identify biomarker-driven subphenotypes in circulatory shock. **Dipeptidyl peptidase 3 (DPP3)** is a cytosolic enzyme released into the bloodstream during cell injury; it degrades essential vasopressor peptides like angiotensin II, leading to refractory hypotension and organ failure. Anti-DPP3 antibodies (such as **procizumab**) are designed to inhibit this enzymatic activity and restore hemodynamic stability. **Bioactive adrenomedullin (bio-ADM)** is a hormone that regulates vascular endothelial barrier function; while necessary for vascular integrity, excessive levels in shock contribute to severe vasodilation and vascular leakage. Anti-bio-ADM antibodies (such as **adrecizumab**) modulate circulating ADM levels to stabilize the endothelial barrier and improve vascular tone. This personalized medicine approach aims to match specific antibody therapies to patients based on their unique molecular signatures of circulatory failure.

Other names

anti-bodies-Saint-Louis Hospital, Paris, FranceAnti-Dipeptidyl peptidase 3 + Anti-Bioactive adrenomedullinAnti-DPP3 + Anti-bio-ADM